LETTER {#sec1}
======

The emergence and spread of carbapenem-resistant Enterobacteriaceae (CRE) are a global health problem that is of great concern to public health services ([@B1], [@B2]). The purpose of this study was to determine the frequency of CRE in three Nigerian hospitals and to characterize the resistance mechanisms of such isolates.

A total of 218 consecutive clinical isolates of Enterobacteriaceae based on inclusion criteria were collected from March to May 2015 at three medical microbiology laboratories of hospitals in Edo State, Nigeria (see Table S1 in the supplemental material). Screening for carbapenem resistance was performed using meropenem and ertapenem discs (10 μg; Oxoid, United Kingdom) according to EUCAST guidelines ([@B3]). The Kirby-Bauer susceptibility testing technique ([@B4]) and Etest method were carried out, and results were interpreted using EUCAST criteria ([@B5]). Identification of the involved resistance mechanisms was determined by whole-genome sequencing (WGS).

Out of 218 consecutive clinical Enterobacteriaceae isolates, 9 (4.1%) were further investigated due to cutoff values above the EUCAST screening recommendations ([Table 1](#T1){ref-type="table"}). All isolates showed resistance to piperacillin-tazobactam and amoxicillin-clavulanic acid, all but isolate Ec4349 showed resistance to fluoroquinolones and cefotaxime, and all but two isolates each showed resistance to ceftazidime (Ec4349 and Ecl2840_1) and ertapenem (Ec4349 and Ecl10_14_15). Only Ec4349, Ecl2845, Ecl2840_1, and EclQ9 were sensitive to cefepime and aztreonam. The carbapenemase inactivation method ([@B6]) revealed positive results for all nine CRE isolates. By application of WGS, one Klebsiella pneumoniae isolate harbored the *bla*~OXA-181~ gene; two K. pneumoniae isolates harbored the *bla*~NDM-1~ gene. The *bla*~OXA-48~ gene was detected in one Escherichia coli isolate, one K. pneumoniae isolate, and four Enterobacter cloacae isolates, respectively. All isolates had a single carbapenemase resistance gene on their draft genome fragment. Thirteen plasmid incompatibility groups were identified among the nine CRE isolates. Multilocus sequence typing (MLST) grouped the nine isolates into five sequence types.

###### 

Characteristics of carbapenem-resistant Enterobacteriaceae isolates

  Isolate[^*a*^](#T1F1){ref-type="table-fn"}   Hospital[^*b*^](#T1F2){ref-type="table-fn"}   Clinical specimen     MIC values (μg/ml)[^*c*^](#T1F3){ref-type="table-fn"}   Resistance genes                                                                                                                                                                                                                                  ST[^*d*^](#T1F4){ref-type="table-fn"}   GenBank accession no.[^*e*^](#T1F5){ref-type="table-fn"}              Plasmid replicon(s)[^*f*^](#T1F6){ref-type="table-fn"}
  -------------------------------------------- --------------------------------------------- --------------------- ------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------- --------------------------------------------------------------------- ------------------------------------------------------------------------------------------
  Kp1337LF                                     UBTH                                          Urine                 MEM, 0.75; ETP, 3; COL, 1                               *aac(6\')lb-cr*, *aac(3)-lla*, *str A*, *aadA1*, *str B*, *bla*~TEM-1B~, *bla*~CTX-M-15~, *bla*~SHV-11~, *bla*~OXA-181~, *bla*~OXA-1,~ *mph*(A), *catA1*, *catB3*, *qnrS1*, *qnrB2*, *oqxA*, *oqxB*, *sul1*, *tet*(A), *dfrA15*                   11                                      [SAMN06704546](https://www.ncbi.nlm.nih.gov/biosample/SAMN06704546)   IncFIB(Mar), ColKP3, IncX3,\* IncFII(K), IncFIB(K), IncR
  Kp852                                        UBTH                                          Urine                 MEM, 24; ETP, 32; COL, 1                                *aadA1*, *aac(3)-lla*, *aacA4*, *aph(3\')-Vla*, *arm A*, *aadA2*, *aac(6\')lb-cr*, *bla*~SHV-28~, *bla*~CTX-M-15~, *bla*~NDM-1~, *bla*~OXA-1~, *msr*(E), *mphE*, *catB3*, *oqxB*, *oqxA*, *aac(6\')-lb-cr*, *qnrB1*, *sul1*, *tet*(A), *dfrA12*   15                                      [SAMN06704523](https://www.ncbi.nlm.nih.gov/biosample/SAMN06704523)   Col(BS512), IncFIB(pKPHS1), IncFII, IncFIA(HI1), IncR, IncFIB(K), IncFIB(Mar), IncHI1B\*
  Kp852K                                       UBTH                                          Urine                 MEM, 32; ETP, 24; COL, 0.75                             *aadA1*, *aac(3)-lla*, *aacA4*, *aph(3\')-Vla*, *arm A*, *aadA2*, *aac(6\')lb-cr*, *bla*~SHV-28~, *bla*~CTX-M-15~, *bla*~NDM-1~, *bla*~OXA-1~, *msr*(E), *mphE*, *catB3*, *oqxB*, *oqxA*, *aac(6\')-lb-cr*, *qnrB1*, *sul1*, *tet*(A), *dfrA12*   15                                      [SAMN06704522](https://www.ncbi.nlm.nih.gov/biosample/SAMN06704522)   Col(BS512), IncFIB(pKPHS1), IncFII, IncFIA(HI1), IncR, IncFIB(K), IncFIB(Mar), IncHI1B\*
  Kp872                                        UBTH                                          Endocervical swab     MEM, 4; ETP, 1.5; COL, 0.38                             *str A*, *str B*, *aadA2*, *aac(3)-lla*, *bla*~CTX-M-15~, *bla*~OXA-48~, *bla*~TEM-1B~, *bla*~SHV-11,~ *oqxB*, *oqxA*, *sul1*, *sul2*, *tet*(D), *dfrA14*                                                                                         340                                     [SAMN06704513](https://www.ncbi.nlm.nih.gov/biosample/SAMN06704513)   IncFIA(HI1), IncR, IncL/M(pOXA-48)\*
  Ecl10_14_15                                  CH                                            Peritoneal fluid      MEM, 1.5; ETP, 0.75; COL, 0.75                          *bla*~ACT-5~, *bla*~OXA-48~, *qnrB1*, *dfrA14*                                                                                                                                                                                                    78                                      [SAMN06704512](https://www.ncbi.nlm.nih.gov/biosample/SAMN06704512)   IncL/M(pOXA-48)\*
  Ecl2845                                      UBTH                                          Urine                 MEM, 0.75; ETP, 2; COL, 0.75                            *bla*~ACT-5~, *bla*~OXA-48~                                                                                                                                                                                                                       78                                      [SAMN06704511](https://www.ncbi.nlm.nih.gov/biosample/SAMN06704511)   IncL/M(pOXA-48)\*
  EclQ9                                        UBTH                                          Unidentified source   MEM, 0.75; ETP, 1.5; COL, 0.75                          *bla*~ACT-5~, *bla*~OXA-48~                                                                                                                                                                                                                       78                                      [SAMN06703827](https://www.ncbi.nlm.nih.gov/biosample/SAMN06703827)   IncL/M(pOXA-48)\*
  Ecl2840_1                                    UBTH                                          Urine                 MEM, 4; ETP, 4; COL, 1                                  *bla*~ACT-5~, *bla*~OXA-48~                                                                                                                                                                                                                       78                                      [SAMN06703828](https://www.ncbi.nlm.nih.gov/biosample/SAMN06703828)   IncL/M(pOXA-48)\*
  Ec4349                                       UBTH                                          Urine                 MEM, 0.25; ETP, 0.75; COL, 0.38                         *str A*, *str B*, *bla*~TEM-1B~, *bla*~OXA-48~, *sul2*, *tet*(A), *dfrA14*                                                                                                                                                                        1408                                    [SAMN06703826](https://www.ncbi.nlm.nih.gov/biosample/SAMN06703826)   Col3M, IncL/M(pOXA-48),\* IncR

Ec, *Escherichia coli*; Kp, *Klebsiella pneumoniae*; Ecl, Enterobacter cloacae.

UBTH, University of Benin Teaching Hospital; CH, Central Hospital, Benin.

MEM, meropenem; ETP, ertapenem; COL, colistin.

ST, sequence type.

Accession numbers are shown for the carbapenem resistance gene.

\*, plasmid replicon type harboring the carbapenem resistance gene.

Previous reports from Nigeria on molecular characterization of carbapenem resistance genes have identified genes such as *bla*~VIM~, *bla*~GES~, *bla*~NDM~, *bla*~OXA-181~, and *bla*~KPC~ ([@B7][@B8][@B10]). *bla*~OXA-48~, obtained from our study, has only been determined phenotypically. To the best of our knowledge, our findings, where six out of nine carbapenemase-producing isolates harbored the *bla*~OXA-48~ gene, represent the first molecular determination of the *bla*~OXA-48~ gene for Nigeria. The presence of different plasmid replicon types in carbapenemase-producing Enterobacteriaceae (CPE) underlines their importance in the dissemination of resistance genes. The IncL/M plasmid type was found in all of our OXA-48-producing isolates, correlating with previous reports indicating that the current spread of OXA-48 β-lactamase producers is mainly related to the diffusion of this plasmid ([@B11]).

Occurrence of CPE has been reported globally ([@B12][@B13][@B14]). In Nigeria, most previous reports characterized CRE phenotypically ([@B15][@B16][@B17]). Only a few studies used molecular methods, which are considered the "gold standard" for identification of carbapenemase-producing bacteria ([@B12], [@B18]). Carbapenem resistance is of particular concern as carbapenems are often the last available treatment option for infections due to multidrug-resistant Enterobacteriaceae ([@B19]). To the best of our knowledge, we are reporting the first genomic characterization of CRE from Nigeria. Detailed characterization of CRE is required to combat this worldwide emerging threat and improve patient outcomes.

Accession number(s). {#sec2}
====================

WGS results from our isolates have been deposited in GenBank under the accession numbers listed in [Table 1](#T1){ref-type="table"}.
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###### Supplemental material

Supplemental material for this article may be found at <https://doi.org/10.1128/AAC.00255-17>.
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